Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | CTSD | P07339 | 4/20 | 0.36 |
| ▸ | METAP2 | P50579 | 2/20 | 0.34 |
| ▸ | METAP1 | P53582 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 2/20 | 0.34 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | REN | P00797 | 1/20 | 0.34 |
| ▸ | LAP3 | P28838 | 2/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.33 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4816788 | 0.86 | BACE1 (0.33) | BACE1HCRTR2 | |
| SCHEMBL4817379 | 0.82 | LMNA (0.40) | MAPTMEN1ALDH1A1KMT2ALMNA | |
| SCHEMBL4814554 | 0.81 | MEN1 (0.38) | MAPTMEN1ALDH1A1KMT2ALMNA | |
| SCHEMBL4811289 | 0.80 | SCN9A (0.38) | MAPTALDH1A1LMNACTSDBACE1 | |
| SCHEMBL4818604 | 0.72 | LAP3 (0.46) | MAPTMEN1ALDH1A1KMT2ACTSD | |
| SCHEMBL7491376 | 0.67 | LMNA (0.41) | MAPTLMNAMETAP2METAP1KDM4E | |
| SCHEMBL27593026 | 0.66 | KMT2A (0.57) | MAPTMEN1ALDH1A1KMT2ALMNA | |
| SCHEMBL13765364 | 0.63 | NAAA (0.58) | MAPTMEN1ALDH1A1KMT2ALMNA | |
| SCHEMBL24346075 | 0.62 | MMP2 (0.60) | MAPTMEN1ALDH1A1KMT2AHPGD | |
| SCHEMBL1041526 | 0.62 | MMP2 (0.60) | MAPTMEN1ALDH1A1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050159459-A1 | Statine derivatives for the treatment of Alzheimer's disease | ALZHEIMER'S COLLABORATION | 2005-07-21 | — | — | US | claimed |
| EP-1404328-A1 | ALPHA-HYDROXYAMIDE STATINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-04-07 | — | — | EP | claimed |
| US-20030083356-A1 | Statine derivatives for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN | 2003-05-01 | — | — | US | claimed |
| WO-2003006021-A1 | ALPHA-HYDROXYAMIDE STATINE DERIVATIVES FOR THE TREATMENT OF ALZH EIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-01-23 | — | — | WO | claimed |
| US-7358264-B2 | Statine derivatives for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN COMPANY (US) | 2008-04-15 | — | — | US | disclosed |
| US-7354943-B2 | Statine derivatives for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN (US) | 2008-04-08 | — | — | US | disclosed |
| US-20050165069-A1 | Statine derivatives for the treatment of Alzheimer's disease | ALZHEIMER'S COLLABORATION | 2005-07-28 | — | — | US | disclosed |
| US-20050159459-A1 | Statine derivatives for the treatment of Alzheimer's disease | ALZHEIMER'S COLLABORATION | 2005-07-21 | — | — | US | disclosed |
| US-6864290-B2 | Statine derivatives for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN, LLP (US) | 2005-03-08 | — | — | US | disclosed |
| EP-1404328-A1 | ALPHA-HYDROXYAMIDE STATINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE | Elan Pharmaceuticals, Inc. (US) | 2004-04-07 | — | — | EP | disclosed |
| US-20030083356-A1 | Statine derivatives for the treatment of Alzheimer's disease | PHARMACIA & UPJOHN | 2003-05-01 | — | — | US | disclosed |
| WO-2003006021-A1 | ALPHA-HYDROXYAMIDE STATINE DERIVATIVES FOR THE TREATMENT OF ALZH EIMER'S DISEASE | ELAN PHARMACEUTICALS, INC. (US) | 2003-01-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165069-A1 | Statine derivatives for the treatment of Alzheimer's disease | BACE1, APP, BACE2 | MAPT 29/4885MEN1 1804/4885ALDH1A1 2281/4885 |
| US-20050159459-A1 | Statine derivatives for the treatment of Alzheimer's disease | BACE1, APP, BACE2 | MAPT 29/4885MEN1 1804/4885ALDH1A1 2281/4885 |
| US-20030083356-A1 | Statine derivatives for the treatment of Alzheimer's disease | BACE1, APP, BACE2 | MAPT 51/4885MEN1 1550/4885ALDH1A1 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.